

# Mamoru Takada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4292652/publications.pdf>

Version: 2024-02-01

7  
papers

353  
citations

1478505

6  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

770  
citing authors

#	ARTICLE	IF	CITATIONS
1	Practical approach to prevent COVID-19 infection at breast cancer screening. <i>Breast Cancer</i> , 2021, 28, 969-976.	2.9	1
2	Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. <i>Nature Communications</i> , 2019, 10, 5177.	12.8	27
3	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , 2018, 361, 290-295.	12.6	134
4	FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A. <i>Cancer Research</i> , 2017, 77, 4881-4893.	0.9	68
5	Egln2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. <i>Oncotarget</i> , 2017, 8, 6787-6795.	1.8	16
6	New Insights into Protein Hydroxylation and Its Important Role in Human Diseases. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 208-220.	7.4	49
7	Egln2 associates with the NRF1-PGC1 $\beta$ complex and controls mitochondrial function in breast cancer. <i>EMBO Journal</i> , 2015, 34, 2953-2970.	7.8	58